241 related articles for article (PubMed ID: 14500688)
41. Curcumin Induces Apoptosis in Pre-B Acute Lymphoblastic Leukemia Cell Lines Via PARP-1 Cleavage.
Mishra D; Singh S; Narayan G
Asian Pac J Cancer Prev; 2016; 17(8):3865-9. PubMed ID: 27644631
[TBL] [Abstract][Full Text] [Related]
42. Triptolide inhibits proliferation of Epstein-Barr virus-positive B lymphocytes by down-regulating expression of a viral protein LMP1.
Zhou H; Guo W; Long C; Wang H; Wang J; Sun X
Biochem Biophys Res Commun; 2015 Jan; 456(3):815-20. PubMed ID: 25511707
[TBL] [Abstract][Full Text] [Related]
43. Therapeutic roles of curcumin: lessons learned from clinical trials.
Gupta SC; Patchva S; Aggarwal BB
AAPS J; 2013 Jan; 15(1):195-218. PubMed ID: 23143785
[TBL] [Abstract][Full Text] [Related]
44. Epstein-Barr virus Zta-induced immunomodulators from nasopharyngeal carcinoma cells upregulate interleukin-10 production from monocytes.
Lee CH; Yeh TH; Lai HC; Wu SY; Su IJ; Takada K; Chang Y
J Virol; 2011 Jul; 85(14):7333-42. PubMed ID: 21543473
[TBL] [Abstract][Full Text] [Related]
45. Curcuminoids suppress the growth of pharynx and nasopharyngeal carcinoma cells through induced apoptosis.
Lin YT; Wang LF; Hsu YC
J Agric Food Chem; 2009 May; 57(9):3765-70. PubMed ID: 19317462
[TBL] [Abstract][Full Text] [Related]
46. Over-expression of phosphatase of regenerating liver-3 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma.
Zhou J; Wang S; Lu J; Li J; Ding Y
Int J Cancer; 2009 Apr; 124(8):1879-86. PubMed ID: 19101992
[TBL] [Abstract][Full Text] [Related]
47. Antioxidant and anti-inflammatory properties of curcumin.
Menon VP; Sudheer AR
Adv Exp Med Biol; 2007; 595():105-25. PubMed ID: 17569207
[TBL] [Abstract][Full Text] [Related]
48. Autoactivation of the Epstein-Barr virus oncogenic protein LMP1 during type II latency through opposite roles of the NF-kappaB and JNK signaling pathways.
Goormachtigh G; Ouk TS; Mougel A; Tranchand-Bunel D; Masy E; Le Clorennec C; Feuillard J; Bornkamm GW; Auriault C; Manet E; Fafeur V; Adriaenssens E; Coll J
J Virol; 2006 Aug; 80(15):7382-93. PubMed ID: 16840319
[TBL] [Abstract][Full Text] [Related]
49. Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells.
Huang TS; Lee SC; Lin JK
Proc Natl Acad Sci U S A; 1991 Jun; 88(12):5292-6. PubMed ID: 1905019
[TBL] [Abstract][Full Text] [Related]
50. Curcumin in treatment of hematological cancers: Promises and challenges.
Entezari M; Tayari A; Paskeh MDA; Kheirabad SK; Naeemi S; Taheriazam A; Dehghani H; Salimimoghadam S; Hashemi M; Mirzaei S; Samarghandian S
J Tradit Complement Med; 2024 Mar; 14(2):121-134. PubMed ID: 38481552
[TBL] [Abstract][Full Text] [Related]
51. Conceptualizing an Integrative Multiple Myeloma Care: The Role of Nutrition, Supplements, and Complementary Modalities.
Andreazzoli F; Levy Yurkovski I; Ben-Arye E; Bonucci M
Nutrients; 2024 Jan; 16(2):. PubMed ID: 38257130
[TBL] [Abstract][Full Text] [Related]
52. Combined Use of Immune Checkpoint Inhibitors and Phytochemicals as a Novel Therapeutic Strategy against Cancer.
Luo L; Lin C; Wang P; Cao D; Lin Y; Wang W; Zhao Y; Shi Y; Gao Z; Kang X; Zhang Y; Wang S; Wang J; Xu M; Liu H; Liu SL
J Cancer; 2023; 14(12):2315-2328. PubMed ID: 37576404
[TBL] [Abstract][Full Text] [Related]
53. Curcumin potentiates the anti-inflammatory effects of Tehranolide by modulating the STAT3/NF-κB signaling pathway in breast and ovarian cancer cell lines.
Afshari H; Noori S; Zarghi A
Inflammopharmacology; 2023 Oct; 31(5):2541-2555. PubMed ID: 37452228
[TBL] [Abstract][Full Text] [Related]
54. From the Bush to the Brain: Preclinical Stages of Ethnobotanical Anti-Inflammatory and Neuroprotective Drug Discovery-An Australian Example.
Kumar P; Mathew S; Gamage R; Bodkin F; Doyle K; Rossetti I; Wagnon I; Zhou X; Raju R; Gyengesi E; Münch G
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446262
[TBL] [Abstract][Full Text] [Related]
55. Augmented Transdermal Delivery of Curcumin for the Effective Management of Plaque Psoriasis - Design, Formulation, Characterisation, and In Vivo Studies.
Kumar B; Sahoo PK
AAPS PharmSciTech; 2023 Jun; 24(5):134. PubMed ID: 37291356
[TBL] [Abstract][Full Text] [Related]
56. Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review.
Kumar A; Gautam V; Sandhu A; Rawat K; Sharma A; Saha L
World J Gastrointest Surg; 2023 Apr; 15(4):495-519. PubMed ID: 37206081
[TBL] [Abstract][Full Text] [Related]
57. The Role of STATs in Ovarian Cancer: Exploring Their Potential for Therapy.
Standing D; Feess E; Kodiyalam S; Kuehn M; Hamel Z; Johnson J; Thomas SM; Anant S
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173951
[TBL] [Abstract][Full Text] [Related]
58. Natural biomolecules and derivatives as anticancer immunomodulatory agents.
Bernitsa S; Dayan R; Stephanou A; Tzvetanova ID; Patrikios IS
Front Immunol; 2022; 13():1070367. PubMed ID: 36700235
[TBL] [Abstract][Full Text] [Related]
59. A curcumin analogue GO-Y030 depletes cancer stem cells by inhibiting the interaction between the HSP70/HSP40 complex and its substrates.
Suzuki M; Yamamoto Y; Nishijima-Matsunobu A; Kawasaki Y; Shibata H; Omori Y
FEBS Open Bio; 2023 Mar; 13(3):434-446. PubMed ID: 36648092
[TBL] [Abstract][Full Text] [Related]
60. The JAK-STAT Signaling Pathway in Epilepsy.
Sun H; Ma D; Cheng Y; Li J; Zhang W; Jiang T; Li Z; Li X; Meng H
Curr Neuropharmacol; 2023; 21(10):2049-2069. PubMed ID: 36518035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
